Jenburkt Pharmaceuticals Limited (BOM:524731)
India
· Delayed Price · Currency is INR 1,086.20
+36.40 (3.47%)
At close: May 16, 2025
Jenburkt Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Revenue | 1,495 | 1,420 | 1,367 | 1,240 | 1,093 | 1,189 | Upgrade
|
| Revenue Growth (YoY) | 8.07% | 3.82% | 10.30% | 13.44% | -8.07% | -3.06% | Upgrade
|
| Cost of Revenue | 308.94 | 313.42 | 338.6 | 321.51 | 307.65 | 337.55 | Upgrade
|
| Gross Profit | 1,186 | 1,106 | 1,029 | 918.3 | 785.29 | 851.36 | Upgrade
|
| Selling, General & Admin | 444.8 | 424.89 | 388.07 | 364.91 | 323.77 | 365.1 | Upgrade
|
| Other Operating Expenses | 347.22 | 350.14 | 336.35 | 280.04 | 263.08 | 288.79 | Upgrade
|
| Operating Expenses | 817.57 | 798.42 | 747.01 | 663.93 | 607.21 | 676.89 | Upgrade
|
| Operating Income | 368.36 | 307.83 | 281.88 | 254.37 | 178.09 | 174.47 | Upgrade
|
| Interest Expense | -3.59 | -2.3 | -3 | -3.48 | -4.24 | -4.94 | Upgrade
|
| Interest & Investment Income | 41.8 | 41.8 | 40.65 | 44.04 | 40.71 | 36.84 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.32 | 3.32 | 7.6 | 2.45 | 2.22 | 3.65 | Upgrade
|
| Other Non Operating Income (Expenses) | 13.25 | -0.38 | 0.46 | -0.87 | -0.48 | 1.35 | Upgrade
|
| EBT Excluding Unusual Items | 423.15 | 350.28 | 327.59 | 296.51 | 216.29 | 211.37 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.33 | 1.33 | 0.04 | 0.02 | 0.06 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 1.84 | - | - | Upgrade
|
| Pretax Income | 424.62 | 351.76 | 328.65 | 298.71 | 216.42 | 211.38 | Upgrade
|
| Income Tax Expense | 110.56 | 91.99 | 82.58 | 75.74 | 51.39 | 62.68 | Upgrade
|
| Net Income | 314.06 | 259.77 | 246.07 | 222.97 | 165.02 | 148.7 | Upgrade
|
| Net Income to Common | 314.06 | 259.77 | 246.07 | 222.97 | 165.02 | 148.7 | Upgrade
|
| Net Income Growth | 28.45% | 5.57% | 10.36% | 35.12% | 10.98% | -24.89% | Upgrade
|
| Shares Outstanding (Basic) | 4 | 4 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 4 | 4 | 5 | 5 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 3.09% | -3.34% | -0.52% | - | - | - | Upgrade
|
| EPS (Basic) | 71.16 | 58.86 | 53.90 | 48.58 | 35.96 | 32.40 | Upgrade
|
| EPS (Diluted) | 71.16 | 58.86 | 53.90 | 48.58 | 35.96 | 32.40 | Upgrade
|
| EPS Growth | 24.61% | 9.21% | 10.93% | 35.12% | 10.98% | -24.89% | Upgrade
|
| Free Cash Flow | - | 55.7 | 149.48 | 62.17 | 183.1 | 104.62 | Upgrade
|
| Free Cash Flow Per Share | - | 12.62 | 32.74 | 13.55 | 39.90 | 22.80 | Upgrade
|
| Dividend Per Share | - | 15.300 | 14.400 | 12.000 | 10.200 | 8.100 | Upgrade
|
| Dividend Growth | - | 6.25% | 20.00% | 17.65% | 25.93% | -20.59% | Upgrade
|
| Gross Margin | 79.33% | 77.92% | 75.24% | 74.07% | 71.85% | 71.61% | Upgrade
|
| Operating Margin | 24.64% | 21.68% | 20.61% | 20.52% | 16.29% | 14.67% | Upgrade
|
| Profit Margin | 21.01% | 18.30% | 17.99% | 17.98% | 15.10% | 12.51% | Upgrade
|
| Free Cash Flow Margin | - | 3.92% | 10.93% | 5.01% | 16.75% | 8.80% | Upgrade
|
| EBITDA | 384.26 | 324.23 | 298.93 | 267.14 | 190.48 | 187.02 | Upgrade
|
| EBITDA Margin | 25.71% | 22.84% | 21.86% | 21.55% | 17.43% | 15.73% | Upgrade
|
| D&A For EBITDA | 15.9 | 16.4 | 17.05 | 12.77 | 12.4 | 12.55 | Upgrade
|
| EBIT | 368.36 | 307.83 | 281.88 | 254.37 | 178.09 | 174.47 | Upgrade
|
| EBIT Margin | 24.64% | 21.68% | 20.61% | 20.52% | 16.29% | 14.67% | Upgrade
|
| Effective Tax Rate | 26.04% | 26.15% | 25.13% | 25.36% | 23.75% | 29.65% | Upgrade
|
| Revenue as Reported | 1,555 | 1,466 | 1,419 | 1,289 | 1,136 | 1,231 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.